Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed [Gastrointestinal Cancer]

Conclusion
Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation.

Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Hurwitz, Uppal, Wagner, Bendell, Beck, Wade, Nemunaitis, Stella, Pipas, Wainberg, Manges, Garrett, Hunter, Clark, Leopold, Sandor, Levy Tags: Combined Modality Gastrointestinal Cancer Source Type: research